- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | BIO-WORKS TECHNOLOGIES AB: Letter of Intent for order of WorkBreads affimAb increased to 11,9 Mkr | 1 | Cision News | ||
| 04.11. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives a Letter of Intent (LOI) - the anticipated order value is €652,000. | 5 | Cision News | ||
| BIO-WORKS TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 16.09. | Spotlight Stock Market: Market Notice 184/24 Information regarding Bio-Works Technologies AB's subscription option | 1 | Cision News | ||
| 12.09. | Spotlight Stock Market: Market Notice 181/24 - Last day of trading in Bio-Works Technologies AB's BTU | 1 | Cision News | ||
| 07.08. | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.08.2024 | 775 | Xetra Newsboard | Das Instrument LY10 AU000000LLO8 LION ONE METALS CDIS EQUITY wird cum Kapitalmassnahme gehandelt am 07.08.2024 und ex Kapitalmassnahme am 08.08.2024 The instrument LY10 AU000000LLO8 LION ONE METALS... ► Artikel lesen | |
| 02.08. | Spotlight Stock Market: Market Notice 164/24 - Information regarding the rights issue from Bio-Works Technologies AB | 1 | Cision News | ||
| 15.07. | Spotlight Stock Market: Market Notice 153/24 - Bio-Works Technologies AB will be listed on Spotlight Stock Market on July 18, 2024 | 1 | Cision News | ||
| 02.07. | Nasdaq Stockholm AB: Delisting of Bio-Works Technologies AB from Nasdaq First North Growth Market | 320 | GlobeNewswire | Bio-Works Technologies AB has applied for its shares to be delisted from Nasdaq
First North Growth Market.
Nasdaq Stockholm AB has approved the application and decided to delist the
shares in Bio-Works... ► Artikel lesen | |
| 27.06. | Nasdaq Stockholm AB: Bio-Works Technologies AB receives observation status | 234 | GlobeNewswire | On June 26, 2024, Bio-Works Technologies AB (the "Company") issued a press
release where the Company announced its intention to change listing from Nasdaq
First North Growth Market to Spotlight Stock... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,220 | -0,39 % | Biotech Report: Evotec und Qiagen behauptet; US-Sektor legt zu | (shareribs.com) Frankfurt / New York 04.12.2024 - Biotech-Aktien zeigten sich im deutschen Handel überwiegend leichter. Unter anderem gaben 4SC und Vita34 nach. Für Evotec ging es leicht nach oben.... ► Artikel lesen | |
| DYNE THERAPEUTICS | 29,500 | +6,34 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,710 | +5,49 % | Beam Therapeutics Appoints Sravan Emany As CFO | WASHINGTON (dpa-AFX) - Biotechnology company Beam Therapeutics, Inc. (BEAM) announced Friday the appointment of Sravan Emany as chief financial officer (CFO), effective December 19, 2024. Emany... ► Artikel lesen | |
| BIONTECH | 115,10 | -0,17 % | Evotec, Vidac Pharma, BioNTech - Krebsforschung: Die Goldgrube im Depot | Investitionen in Aktiengesellschaften, die im Bereich der Onkologieforschung tätig sind, bieten vielversprechende Renditechancen und langfristige Stabilität. Der Onkologiemarkt gehört zu den wachstumsstärksten... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,010 | +21,55 % | Recursion Pharmaceuticals, Inc.: Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma | First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesizedREC-1245... ► Artikel lesen | |
| IMMUNOVANT | 28,620 | +0,77 % | Immunovant Inc.: Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 | Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data from batoclimab trial in Graves' disease... ► Artikel lesen | |
| EVOTEC | 8,770 | -1,79 % | Evotec-Aktie unter Druck: Geplatzte Übernahme und Führungswechsel belasten Kurs | Die Evotec SE, ein führendes Biotechnologieunternehmen aus Hamburg, steht vor einer turbulenten Phase. Nach dem Rückzug eines Übernahmeangebots durch Halozyme Therapeutics und einem überraschenden Führungswechsel... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 46,670 | +5,88 % | Kymera International erwirbt Coating Center Castrop GmbH | Research Triangle Park, North Carolina (ots/PRNewswire) - -- Kymera erweitert Präsenz seiner Sparte Oberflächentechnologien in Europa und erleichtert Kunden den Zugang zu fortschrittlichen Lösungen... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 69,85 | +2,52 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results | Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025 Registrational Cohort 2 of EMBOLD study... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,460 | +0,73 % | PTA-News: Small- & MicroCap Investment: Die +440 %-Chance: NurExone mit dreistelligem Gewinn wie Vera Therapeutics oder Viking Therapeutics? | DJ PTA-News: Small- & MicroCap Investment: Die +440 %-Chance: NurExone mit dreistelligem Gewinn wie Vera Therapeutics oder Viking Therapeutics?
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt... ► Artikel lesen | |
| JANUX THERAPEUTICS | 64,75 | -2,34 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 19,090 | +6,95 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| NEUMORA THERAPEUTICS | 10,290 | +6,52 % | Neumora Therapeutics, Inc.: Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025 Ongoing clinical studies evaluating... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,800 | +2,51 % | Looking Into ADMA Biologics' Recent Short Interest | ||
| PHATHOM PHARMACEUTICALS | 9,000 | +5,88 % | Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update | Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly reportNet revenues of $7.3 million reported for the second quarter... ► Artikel lesen |
Das Unternehmen BIO-WORKS TECHNOLOGIES AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,77 % bei einem Aktienkurs von 0,057 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIO-WORKS TECHNOLOGIES AB finden Sie auf Wallstreet Online.
